Switch theme
Sign up to access all valuation multiples
Bio-Thera Solutions Ltd is engaged in research, development, and production of drugs and biosimilars. The company provides drug research and development; biotechnology consulting and communication services; services; medical research and experimental development; biological drug manufacturing; and pharmaceuticals retail.
2003
n/a
LTM Revenue $108M
LTM EBITDA -$51.9M
$1.3B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Bio-Thera Solutions has a last 12-month revenue of $108M and a last 12-month EBITDA of -$51.9M.
In the most recent fiscal year, Bio-Thera Solutions achieved revenue of $102M and an EBITDA of -$55.2M.
Bio-Thera Solutions expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Bio-Thera Solutions valuation multiples based on analyst estimates| FY 2023 | FY 2024 | FY 2025 | LTM | NTM | |
|---|---|---|---|---|---|
| Revenue | $102M | $102M | XXX | XXX | XXX |
| Gross Profit | $36.4M | $70.5M | XXX | XXX | XXX |
| Gross Margin | 36% | 69% | XXX | XXX | XXX |
| EBITDA | -$55.2M | -$55.7M | XXX | XXX | XXX |
| EBITDA Margin | -54% | -54% | XXX | XXX | XXX |
| Net Profit | -$66.2M | -$54.4M | XXX | XXX | XXX |
| Net Margin | -65% | -53% | XXX | XXX | XXX |
| Net Debt | n/a | $36.5M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of April 15, 2025, Bio-Thera Solutions's stock price is CNY 23 (or $3).
Bio-Thera Solutions has current market cap of CNY 9.5B (or $1.3B), and EV of CNY 9.7B (or $1.3B).
See Bio-Thera Solutions trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $1.3B | $1.3B | XXX | XXX | XXX | XXX | $-0.16 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Sign UpAs of April 15, 2025, Bio-Thera Solutions has market cap of $1.3B and EV of $1.3B.
Bio-Thera Solutions's trades at 12.4x LTM EV/Revenue multiple, and -25.9x LTM EBITDA.
Analysts estimate Bio-Thera Solutions's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See valuation multiples for Bio-Thera Solutions and 10K+ public comps| FY 2024 | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|
| EV | $1.3B | XXX | XXX | XXX |
| EV/Revenue | 13.1x | XXX | XXX | XXX |
| EV/EBITDA | -24.1x | XXX | XXX | XXX |
| P/E | -18.6x | XXX | XXX | XXX |
| P/E/Growth | n/a | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Sign UpBio-Thera Solutions's NTM/LTM revenue growth is 20%
Bio-Thera Solutions's revenue per employee for the last fiscal year averaged n/a, while opex per employee averaged n/a for the same period.
Over next 12 months, Bio-Thera Solutions's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .
Analysts estimate Bio-Thera Solutions's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See operational valuation multiples for Bio-Thera Solutions and other 10K+ public comps| FY 2024 | NTM | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|---|
| Revenue Growth | 0% | XXX | XXX | XXX | XXX |
| EBITDA Margin | -54% | XXX | XXX | XXX | XXX |
| EBITDA Growth | 1% | XXX | XXX | XXX | XXX |
| Rule of 40 (SaaS-only) | -34% | XXX | XXX | XXX | XXX |
| Revenue per Employee | n/a | XXX | XXX | XXX | XXX |
| Opex per Employee | n/a | XXX | XXX | XXX | XXX |
| S&M Expenses to Revenue | 28% | XXX | XXX | XXX | XXX |
| G&A Expenses to Revenue | 1% | XXX | XXX | XXX | XXX |
| R&D Expenses to Revenue | 105% | XXX | XXX | XXX | XXX |
| Opex to Revenue | 136% | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Armata Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Bio-Thera Solutions acquired XXX companies to date.
Last acquisition by Bio-Thera Solutions was XXXXXXXX, XXXXX XXXXX XXXXXX . Bio-Thera Solutions acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Sign Up| When was Bio-Thera Solutions founded? | Bio-Thera Solutions was founded in 2003. |
| Where is Bio-Thera Solutions headquartered? | Bio-Thera Solutions is headquartered in China. |
| Who is the CEO of Bio-Thera Solutions? | Bio-Thera Solutions's CEO is Ms. Cui Hua Liu. |
| Is Bio-Thera Solutions publicy listed? | Yes, Bio-Thera Solutions is a public company listed on SHG. |
| What is the stock symbol of Bio-Thera Solutions? | Bio-Thera Solutions trades under 688177 ticker. |
| When did Bio-Thera Solutions go public? | Bio-Thera Solutions went public in 2020. |
| Who are competitors of Bio-Thera Solutions? | Similar companies to Bio-Thera Solutions include e.g. Julphar, Galapagos, Pharming, Vivoryon Therapeutics. |
| What is the current market cap of Bio-Thera Solutions? | Bio-Thera Solutions's current market cap is $1.3B |
| What is the current revenue of Bio-Thera Solutions? | Bio-Thera Solutions's last 12-month revenue is $108M. |
| What is the current EBITDA of Bio-Thera Solutions? | Bio-Thera Solutions's last 12-month EBITDA is -$51.9M. |
| What is the current EV/Revenue multiple of Bio-Thera Solutions? | Current revenue multiple of Bio-Thera Solutions is 12.4x. |
| What is the current EV/EBITDA multiple of Bio-Thera Solutions? | Current EBITDA multiple of Bio-Thera Solutions is -25.9x. |
| What is the current revenue growth of Bio-Thera Solutions? | Bio-Thera Solutions revenue growth between 2023 and 2024 was 0%. |
| Is Bio-Thera Solutions profitable? | Yes, Bio-Thera Solutions is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
